Navigation Links
Par Pharmaceutical Companies Reports Second Quarter 2011 Results
Date:8/3/2011

$84.5 million in the first quarter 2011. The decrease is due to primarily to the voluntary withdrawal of clonidine in the second quarter and the seasonality of hydrocodone/chlorpheniramine.
  • Megace® ES: Net sales were $14.1 million for the second quarter compared to $14.1 million in the first quarter.

  • Nascobal® B12 Nasal Spray: Net sales were $6.3 million for the second quarter compared to $3.9 million in the first quarter.  The increase was due, in part, to a shortage of a competing vitamin B12 intramuscular injection product.

  • Revenues and gross margin for the second quarter 2011 were $224.2 million and $99.0 million, respectively, compared to $233.0 million in net sales and $109.7 million in gross margin during the prior quarter (Q1 2011). The gross margin rate on the Company's consolidated product portfolio decreased to 44.2% versus 47.1% in the first quarter 2011.  The decrease was due primarily to the non-recurrence of the first quarter launches of propafenone and amlodipine/benazepril and the second quarter launch of lower margin budesonide.  2Q 20111Q 2011$%$%Key Par (Generic) Products (1)(2)$   40.7

    32.3%$   50.6

    40.4%All other Par (Generic)43.3

    56.5%42.0

    49.6%Total Par (Generic)$   84.0

    41.5%$   92.6

    44.1%Strativa (Branded) Products$   15.0

    69.1%$   17.1

    73.7%Total (All Products) $   99.0

    44.2%$ 109.7

    47.1%1. Q211 Key Par Products is comprised of Metoprolol, Budesonide EC, Sumatriptan, Propafenone, Amlodipine/benazapril, Meclizine.

    2. Q111 Key Par Products does not include Budesonide EC as it was launched in Q2.Operating ExpensesExcluding the one-time restructuring charge of $27.7 million, total operating expenses decreased during the second quarter of 2011 as compared to the prior quarter as follows:

  • Research and development expenses were $8.1 million in the seco
    '/>"/>

  • SOURCE Par Pharmaceutical Companies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
    2. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
    3. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
    4. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    5. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
    6. Novo Nordisk and Partnership of Ivy Equities, LCOR and Intercontinental RE Corp. Announce Lease Agreement for N.J. Pharmaceutical Companys New U.S. Headquarters
    7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
    8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
    9. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
    10. Though Essential to Pharmaceutical Sales Success, the Use of Health Outcomes Data Often Overlooked by Sales Leaders
    11. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/3/2015)... July 3, 2015 According ... & Cardiac Rhythm Management Market ECG, Implantable Loop ... Implantable Cardioverter Defibrillator, Dual Chamber Pacemaker, CRT-D, CRT-P ... the global Cardiac Monitoring (CM) and Cardiac Rhythm ... $26,646.5 Million by 2020 from $21,137.7 Million in ...
    (Date:7/3/2015)... , July 3, 2015 ... with Broda Technologies Co., Ltd., operating in both the ... the company,s proprietary IntelliGel ® supramolecular hydrogel technology ... development and other ophthalmic therapies. The Broda technology offers ... solution is a free-forming liquid and with low concentrations ...
    (Date:7/2/2015)... ResMed Inc. (NYSE: RMD ) today announced ... ended June 30, 2015 results on Thursday, July 30, 2015, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
    Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Redwood Pharma Licenses Novel Hydrogel Drug Delivery Technology From Broda Technologies 2ResMed to Announce Fourth Quarter and Fiscal Year-End 2015 Results 2
    ... 2011 Milestone Scientific Inc. (Pink Sheets: ... injection systems for medical and dental markets, today announced ... OTCQB(TM) electronic quotation and trading system under the ticker ... action as a result of the addition of the ...
    ... Texas, March 14, 2011 (Nasdaq: VRML ... inclusion of OVA1® as part of the recently published ... Obstetrics and Gynecology , the American College of Obstetricians ... published an update committee opinion on the role of ...
    Cached Medicine Technology:Milestone Scientific Inc. Commences Trading on the OTC Pink 2OVA1 Included in Latest ACOG/SGO Committee Opinion 2OVA1 Included in Latest ACOG/SGO Committee Opinion 3OVA1 Included in Latest ACOG/SGO Committee Opinion 4
    (Date:7/3/2015)... ... 2015 , ... Smoothies are all the rage right now and all you ... ingredients. Aurora Natural is proud to introduce a new line of all natural products ... vitamins and minerals! , Aurora is offering a variety of blends and stand-alone items ...
    (Date:7/3/2015)... , ... July 03, 2015 , ... Jennifer Renee Hanes, ... Choice Emergency Room , the largest network of independent freestanding emergency rooms in the ... medical director of our Sienna Plantation facility,” said Executive Medical Director of First Choice ...
    (Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... " Selfie ... Report, which features the latest and coolest technology products available to consumers. Amanda Forstrom, ... viewers how these selfie sticks are great for documenting memories. , Almost every smartphone ...
    (Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness and the ... members of the Red Deer community with free fitness training and indoor fitness boot ... food, events and entertainment raised thousands of charity dollars and ended with a $10,000 ...
    (Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased ... is the first sweetFrog store located in Mississippi. The premium frozen yogurt chain was ... , The store, located at 104 Railroad Avenue, New Albany, MS 38652, will have ...
    Breaking Medicine News(10 mins):Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 2Health News:Dr. Jennifer Renee Hanes Named by First Choice Emergency Room as Medical Director of Missouri City, TX Facility 3Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:sweetfrog Opens First Location in Mississippi 2
    ... of iron oxide could become tools for simultaneous tumor ... toxic effects against brain cancer cells. In mice, researchers ... these particles can deliver antibodies to implanted brain tumors, ... The results are published online by the journal ...
    ... Gordon HealthDay Reporter , MONDAY, Aug. 2 (HealthDay ... good for the brain, suggests new research. People ... index), meaning those with the greatest blood flow from their ... a healthier brain. In fact, the researchers said that ...
    ... New Orleans, LA The Louisiana Tumor Registry (LTR) ... of Public Health has been awarded a $12 million ... to continue its work as a SEER (Surveillance, Epidemiology ... competitively awarded SEER cancer registries in the United States., ...
    ... several challenges to be overcome if therapeutic anticancer vaccines, ... response, are to be successfully developed. For example, the ... patient,s immune system are themselves targeted by the patient,s ... a team of researchers, led by Michael Morse, at ...
    ... By Amanda Gardner HealthDay Reporter , MONDAY, ... virus to fashion a therapeutic vaccine that appears to attack ... the required tumor-fighting immune response in early human trials, but ... expert urged caution. "They were able to generate an ...
    ... today announced that the United States (U.S.) Food and ... botulinum toxin type A for the treatment of adults ... study conducted in Rochester, Minnesota, the prevalence of focal ... at 295 per million people in the U.S. ...
    Cached Medicine News:Health News:Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment 2Health News:Heart Health Can Help Predict Brain Health: Study 2Health News:Heart Health Can Help Predict Brain Health: Study 3Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 2Health News:LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI 3Health News:Vaccine Shows Some Promise Against Advanced Cancers 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 2Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 3Health News:FDA approves Merz Pharmaceuticals' Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm 4
    Duckbill. 3.5 mm tip. Light curve....
    2 mm. Angled 13 degrees, 15 mm from angle to tip. Round handle....
    2 mm curved tip. Round handle. Designated most popular model or size....
    Large. Double-ended. 3 mm pointed end and 5 mm angled end....
    Medicine Products: